Form 4: Tarsus Pharmaceuticals Director Wendy Yarno Reports Routine Equity Compensation and Share Acquisition

Tarsus Pharmaceuticals Director Wendy Yarno reported the acquisition of 3,350 common shares from RSU settlement, alongside new grants of 4,540 stock options and 2,954 Restricted Stock Units, reflecting her ongoing compensation as a non-employee director.

Summary

• Wendy L. Yarno, a Director of Tarsus Pharmaceuticals, Inc. (TARS), reported several equity transactions in a recent SEC Form 4 filing.
• On June 13, 2025, Ms. Yarno acquired 3,350 shares of Tarsus Pharmaceuticals common stock through the settlement of previously vested Restricted Stock Units (RSUs).
• Following this transaction, Ms. Yarno directly beneficially owns 13,700 shares of common stock.
• On June 12, 2025, she was granted 4,540 stock options with an exercise price of $40.95 per share.
• These stock options are scheduled to vest in full on the one-year anniversary of the grant date, June 12, 2026, subject to her continuous service.
• Also on June 12, 2025, Ms. Yarno received a grant of 2,954 Restricted Stock Units (RSUs), which will vest in full on June 12, 2026, subject to continuous service.
• A prior grant of 3,350 RSUs, originally granted on June 13, 2024, vested and settled into common stock on June 13, 2025.

Sentiment

Score: 7

Explanation: The document is a routine insider transaction filing. The grants of new equity compensation to a director are generally positive as they align interests, but it does not contain information that would significantly alter the company's fundamental outlook.

Positives

• Director Wendy Yarno received new equity compensation, including 4,540 stock options and 2,954 Restricted Stock Units, which aligns her interests with those of shareholders.
• The vesting and settlement of 3,350 Restricted Stock Units into common stock indicates a successful milestone for previously granted equity awards.

Future Outlook

The document primarily details past and current insider transactions and does not provide forward-looking statements regarding company performance or strategic outlook, beyond the vesting schedules of equity awards.

Industry Context

This Form 4 filing reflects routine equity compensation for a non-employee director in the pharmaceutical industry. Such compensation structures are common across publicly traded companies, particularly in biotech and pharma, to align director incentives with long-term shareholder value. The specific value of the options and RSUs will depend on Tarsus Pharmaceuticals' stock performance.

Comparison to Industry Standards

• The equity compensation structure, involving stock options and Restricted Stock Units (RSUs) with one-year vesting periods for non-employee directors, is a standard practice in the U.S. pharmaceutical and biotechnology sectors.
• Companies like Amgen, Gilead Sciences, and Biogen often utilize similar equity-based compensation to attract and retain experienced board members, aligning their interests with long-term company performance.
• The specific number of units and exercise price are company-specific and depend on factors like market capitalization, stock price, and board compensation policies, making direct numerical comparison without more context difficult.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging long-term value creation. The increase in outstanding shares from RSU settlement is minimal.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The granted stock options and Restricted Stock Units are scheduled to vest on June 12, 2026, subject to continuous service.
• The stock options have an expiration date of June 11, 2035.

Key Dates

Recommendation

Keywords

Tarsus Pharmaceuticals, TARS, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Beneficial Ownership